KRAS+ NSCLC
Advertisement
Kathryn C. Arbour, MD, of the Memorial Sloan Kettering Cancer Center, presented results from the study at AACR 2025.
Margarita Majem, MD, PhD, presented the results as a late-breaking abstract during the European Lung Cancer Congress 2025.
Marina Garassino, MD, presented results from the phase 2 portion of the trial at the European Lung Cancer Congress.
Researchers evaluated if demographics, clinical characteristics, and outcomes varied between those with KRAS G12C and G12D.
A team integrating clinical, dual-energy spectral computed tomography, and radiomics features into a predictive model.
Glecirasib, also known as JAB-21822, is an oral, covalent KRAS G12C inhibitor.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
Researchers say the results support the evaluation of the treatment in the phase 3 CodeBreaK 202 trial.
MK-1084 as monotherapy and in combination with pembrolizumab is effective in patients with NSCLC.
Results of a study that evaluated the impact of comprehensive versus limited NGS for advanced NSCLC.
Researchers examined the demographic and clinical outcomes in patients with KRAS-mutated tumors, using patients with NSCLC.
Patients of Hispanic/Latino ethnicity have a greater prevalence of certain lung cancer driver mutations.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.